XOMA Royalty (NASDAQ:XOMA) Upgraded at Zacks Research

Zacks Research upgraded shares of XOMA Royalty (NASDAQ:XOMA) from a strong sell rating to a hold rating in a research report released on Monday morning,Zacks.com reports.

A number of other equities research analysts have also recently issued reports on XOMA. UBS Group set a $76.00 price objective on XOMA Royalty in a report on Tuesday, December 9th. Leerink Partners decreased their price objective on XOMA Royalty from $58.00 to $45.00 and set an “outperform” rating on the stock in a report on Thursday, December 11th. Weiss Ratings reissued a “hold (c-)” rating on shares of XOMA Royalty in a report on Monday, December 29th. Benchmark restated a “buy” rating on shares of XOMA Royalty in a research note on Friday, December 12th. Finally, HC Wainwright dropped their price objective on shares of XOMA Royalty from $104.00 to $97.00 and set a “buy” rating for the company in a research note on Thursday, December 11th. Three research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, XOMA Royalty presently has an average rating of “Moderate Buy” and an average target price of $60.60.

XOMA Royalty Stock Up 1.7%

XOMA opened at $23.27 on Monday. The stock’s fifty day simple moving average is $26.71 and its 200 day simple moving average is $31.15. XOMA Royalty has a 1-year low of $18.35 and a 1-year high of $39.92. The stock has a market cap of $288.08 million, a PE ratio of 31.45 and a beta of 0.86. The company has a current ratio of 3.91, a quick ratio of 3.91 and a debt-to-equity ratio of 1.07.

XOMA Royalty (NASDAQ:XOMA) last issued its quarterly earnings data on Wednesday, November 12th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.33). The company had revenue of $9.35 million during the quarter, compared to the consensus estimate of $11.47 million. XOMA Royalty had a net margin of 32.28% and a return on equity of 2.91%. As a group, research analysts expect that XOMA Royalty will post -1.41 earnings per share for the current year.

Insiders Place Their Bets

In other XOMA Royalty news, CEO Owen Hughes purchased 100,000 shares of the company’s stock in a transaction on Thursday, December 4th. The shares were purchased at an average cost of $25.05 per share, with a total value of $2,505,000.00. Following the completion of the purchase, the chief executive officer owned 102,000 shares in the company, valued at $2,555,100. This represents a 5,000.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 9.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. State of Alaska Department of Revenue bought a new stake in XOMA Royalty in the fourth quarter valued at $27,000. Russell Investments Group Ltd. grew its stake in shares of XOMA Royalty by 3,436.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 756 shares during the period. Tower Research Capital LLC TRC increased its position in XOMA Royalty by 203.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 1,523 shares in the last quarter. JPMorgan Chase & Co. raised its stake in XOMA Royalty by 13.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock worth $112,000 after buying an additional 543 shares during the period. Finally, Raymond James Financial Inc. bought a new position in XOMA Royalty in the second quarter worth approximately $116,000. 95.92% of the stock is owned by institutional investors.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.